LabGenomics Co. Ltd (084650) - Total Liabilities
Based on the latest financial reports, LabGenomics Co. Ltd (084650) has total liabilities worth ₩76.00 Billion KRW (≈ $51.50 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LabGenomics Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how LabGenomics Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See LabGenomics Co. Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
LabGenomics Co. Ltd Competitors by Total Liabilities
The table below lists competitors of LabGenomics Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Absolicon Solar Collector AB Series B
ST:ABSL-B
|
Sweden | Skr5.47 Million |
|
AIxCrypto Holdings, Inc.
NASDAQ:AIXC
|
USA | $4.92 Million |
|
Metal Hawk Ltd
AU:MHK
|
Australia | AU$118.96K |
|
RH Bophelo Ltd
JSE:RHB
|
South Africa | ZAC161.81 Million |
|
Vectus Biosystems Ltd
AU:VBS
|
Australia | AU$1.04 Million |
|
CASA DE BUCOVINA-CLUB DE MUNTE
RO:BCM
|
Romania | RON121.74K |
|
Exact Therapeutics AS
OL:EXTX
|
Norway | Nkr37.65 Million |
|
Dhruv Consultancy Services Limited
NSE:DHRUV
|
India | Rs464.56 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down LabGenomics Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of LabGenomics Co. Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LabGenomics Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LabGenomics Co. Ltd (2014–2024)
The table below shows the annual total liabilities of LabGenomics Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩79.35 Billion ≈ $53.77 Million |
-6.99% |
| 2023-12-31 | ₩85.31 Billion ≈ $57.82 Million |
+106.46% |
| 2022-12-31 | ₩41.32 Billion ≈ $28.00 Million |
-11.27% |
| 2021-12-31 | ₩46.57 Billion ≈ $31.56 Million |
+67.40% |
| 2020-12-31 | ₩27.82 Billion ≈ $18.85 Million |
+45.96% |
| 2019-12-31 | ₩19.06 Billion ≈ $12.92 Million |
+12.17% |
| 2018-12-31 | ₩16.99 Billion ≈ $11.52 Million |
-3.02% |
| 2017-12-31 | ₩17.52 Billion ≈ $11.87 Million |
-3.59% |
| 2016-12-31 | ₩18.17 Billion ≈ $12.32 Million |
+90.55% |
| 2015-12-31 | ₩9.54 Billion ≈ $6.46 Million |
-3.26% |
| 2014-12-31 | ₩9.86 Billion ≈ $6.68 Million |
-- |
About LabGenomics Co. Ltd
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.